- Home
- EIC vs ERAS Comparison
EIC vs ERAS Comparison
Compare EIC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- ERAS
- Stock Information
- Founded
- EIC N/A
- ERAS 2018
- Country
- EIC United States
- ERAS United States
- Employees
- EIC N/A
- ERAS N/A
- Industry
- EIC Finance/Investors Services
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- EIC Finance
- ERAS Health Care
- Exchange
- EIC Nasdaq
- ERAS Nasdaq
- Market Cap
- EIC 355.7M
- ERAS 396.6M
- IPO Year
- EIC 2019
- ERAS 2021
- Fundamental
- Price
- EIC $14.39
- ERAS $1.39
- Analyst Decision
- EIC Strong Buy
- ERAS Strong Buy
- Analyst Count
- EIC 1
- ERAS 6
- Target Price
- EIC $17.50
- ERAS $4.83
- AVG Volume (30 Days)
- EIC 180.9K
- ERAS 1.4M
- Earning Date
- EIC 05-20-2025
- ERAS 05-20-2025
- Dividend Yield
- EIC 16.69%
- ERAS N/A
- EPS Growth
- EIC N/A
- ERAS N/A
- EPS
- EIC 1.97
- ERAS N/A
- Revenue
- EIC $46,223,036.00
- ERAS N/A
- Revenue This Year
- EIC $39.61
- ERAS N/A
- Revenue Next Year
- EIC $27.28
- ERAS N/A
- P/E Ratio
- EIC $7.32
- ERAS N/A
- Revenue Growth
- EIC 72.79
- ERAS N/A
- 52 Week Low
- EIC $12.73
- ERAS $1.01
- 52 Week High
- EIC $16.71
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- EIC 51.50
- ERAS 51.46
- Support Level
- EIC $14.27
- ERAS $1.37
- Resistance Level
- EIC $14.67
- ERAS $1.61
- Average True Range (ATR)
- EIC 0.21
- ERAS 0.14
- MACD
- EIC 0.10
- ERAS 0.00
- Stochastic Oscillator
- EIC 72.16
- ERAS 45.68
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.